Hoʻokumu ʻia ka R&D o Sorrento i ka hoʻokele ʻana i nā mea hou i COVID-19, ka mālama ʻana i ka maʻi kanesa, ka hoʻomalu ʻeha piha a me nā maʻi autoimmune.

Nā Papahana Nui	Hōʻike	Hoʻokumu	Wā I I	Māhele II	Māhele III/Pivotal	Hōʻailona FDA
Nā Polokalamu COVID-19
COVISTIX™ (ʻike maʻi) Hoʻāʻo Antigen wikiwiki 0%* ʻO ka mana hoʻohana pilikia (EUA) ma Mexico (COFEPRIS), Brazil (ANVISA), a me CE Marked ma ʻEulopa COVIMARK™ (ʻike maʻi) Hoʻāʻo Antigen wikiwiki 0%* Hoʻouna ʻia ka palapala noi ma US a me Kanada no ka ʻae ʻana i ka hoʻohana ʻana i ka pilikia (EUA) VIREX (ʻike maʻi) Ma ka Home Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 COVISHIELD™ (Lapaʻau) Neutralizing Antibody (IV) i nā maʻi ma waho a me nā maʻi maʻi 20%* FUJOVEE™ (Abivertinib) ʻO COVID-19 koʻikoʻi i loko o nā maʻi ICU 82%* Ho'āʻo Pivotal e kali ana i ka hoʻomaʻemaʻe FDA OQORY™ (COVI-MSC) ARDS ma muli o COVID-19 i loko o nā maʻi ICU 82%* Hoʻokolokolo Pivotal ma Brazil Me kākoʻo ana Mea kāohi (palapala waha) Anti-viral 40%* Omicron mRNA Vaccine laʻau koʻokoʻo 20%*
Nā Papahana Nui	Hōʻike	Hoʻokumu	Wā I I	Māhele II	Māhele III/Pivotal	Hōʻailona FDA
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) ʻO nā Lymphoma pūnaewele B 60.2%* FUJOVEE™ (Abivertinib) Hoʻomākaukau 20%* FUJOVEE™ (Abivertinib) Lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *Ma ka hui pū ʻana me Lee's Pharm ma Kina PD-L1 (STI-3031)** ʻĀmaʻomaʻo Cervical 82%* ** Ma US a me ka hui pū ʻana me ImmuneOncia ma Korea CD47 Nā Puolo Paʻa 40%* CD38 DAR-T Ka Myeloma Maha 40%* CD38 ADC Amyloidosis, Myeloma Nui, T-ALL, a me ka esophageal 40%* ʻO ka maʻi oncolytic Seprehvec™ Nā Tumors Paʻa; ʻO nā puʻupuʻu CNS 40%* BCMA ADC Nā ʻōpū wai 20%* Bevacizumab-ADNAB™ ʻO ke Kanesa Endometrial 40%* Ma ka hui pū ʻana me Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* Ma ka hui pū ʻana me Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Ma ka hui pū ʻana me Mayo Clinic Sofusa® kūʻē i ka PD-1 ʻO Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Nā Papahana Nui	Hōʻike	Hoʻokumu	Wā I I	Māhele II	Māhele III/Pivotal	Hōʻailona FDA
Pain
ZTlido® 1.8% Neuralgia Postherpetic - PHN 99.8%* Gloperba® Lapaʻau ʻana i ka gout (waha) 99.8%* SEMDEXA (SP-102) ʻEha Lumbar Radicular/Sciatica 82%* SP-103 (Lidocaine Topical System 5.4%) ʻEhaʻeha ʻeha 60.2%* SP-104 (Naltrexone Hoʻopaneʻe ʻia ʻo Burst Low Dose) Fibromyalgia 20%* RTX (resiniferatoxin) ʻAi ʻana i ka epidural ʻEha Intractable in Advanced Cancer 60.3%* Ka inoa keiki makua ole RTX (resiniferatoxin) Alahele intra-articular ʻO ka ʻeha OA o nā kuli ma ke ʻano haʻahaʻa 60.2%*
Nā Papahana Nui	Hōʻike	Hoʻokumu	Wā I I	Māhele II	Māhele III/Pivotal	Hōʻailona FDA
Ka Laau Laau Lymphatic
Sofusa® kūʻē i ka TNF ʻAiʻi (RA) 40%* Sofusa® kūʻē i ka PD-1 ʻO Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® kūʻē iā CTLA-4 Melanoma 40%* Ma ka hui pū ʻana me Mayo Clinic

Nā Polokalamu COVID-19
Nā Papahana Nui (Hōʻike)	Māhele
COVISTIX™ (ʻike maʻi) FDA EUA COVIMARK™ (ʻike maʻi) FDA EUA VIREX (ʻike maʻi) PH III COVISHIELD™ (Lapaʻau) PH I FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Me kākoʻo ana Ka mea hoʻopaʻa (palapala waha) Ph II Omicron mRNA Vaccine Hoʻokumu

immunotherapy
Nā Papahana Nui (Hōʻike)	Māhele
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Hoʻokumu FUJOVEE™ (Abivertinib) Hoʻokumu FUJOVEE™ (Abivertinib) Hoʻokumu FUJOVEE™ (Abivertinib) Hoʻokumu PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Nā Tumors Paʻa) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, a me ka esophageal) Ph I ʻO ka maʻi oncolytic Seprehvec™ (Nā ʻōpū paʻa; nā ʻōpū CNS) PH I BCMA ADC (Liquid Tumors) Hoʻokumu Bevacizumab-ADNAB™ (Ka maʻi maʻi endometrial) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® kūʻē i ka PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Nā Papahana Nui (Hōʻike)	Māhele
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Hōʻailona FDA Gloperba® 1.8% Lapaʻau ʻana i ka gout (waha) Hōʻailona FDA SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Naltrexone Hoʻopaneʻe ʻia ʻo Burst Low Dose) Hoʻokumu RTX (resiniferatoxin) ʻAi ʻana i ka epidural Ph II RTX (resiniferatoxin) Alahele intra-articular Ph II

Hoʻouna Lymphatic
Nā Papahana Nui (Hōʻike)	Māhele II
Sofusa® kūʻē i ka TNF (Autoimmune RA) Ph I Sofusa® kūʻē i ka PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® kūʻē iā CTLA-4 (Melanoma) Ph I